


# HIV PRE-EXPOSURE PROPHYLAXIS ALGORITHM: MEN WHO HAVE SEX WITH MEN

Recent findings from clinical trials have shown that daily oral antiretroviral preexposure prophylaxis (PrEP) with a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in men who have sex with men (MSM), men and women in heterosexual HIV-discordant couples, and heterosexual men and women demonstrated substantial reduction in the rate of HIV acquisition. The iPrEx study showed that prophylaxis with TDF/FTC provided an average of 44% reduction in the risk of HIV acquisition among MSM and transgender women who have sex with men. The CDC has published a clinical practice guideline for PrEP use for the prevention of HIV infection in MSM, heterosexual women and men, and IV drug users.



## REFERENCES

Centers for Disease Control and Prevention: US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2017 Update: A Clinical Practice Guideline. <https://www.cdc.gov/hiv/pdf/guidelines/cdc-hiv-prep-guidelines-2017.pdf>. Published March 2018. Accessed April 19, 2008.

(Rev. 4/2018)